Buparlisib. Molecular model of the experimental cancer drug Buparlisib. Buparlisib is a phosphoinositide 3-kinase inhibitor (PI3K inhibitor) undergoin
Buparlisib. Molecular model of the experimental cancer drug Buparlisib. Buparlisib is a phosphoinositide 3-kinase inhibitor (PI3K inhibitor) undergoing clinical trials for treatment of advanced endocrine-resistant breast cancer. PI3K inhibitors are a class of drugs that function by inhibiting one or more of the phosphoinositide 3-kinase enzymes, which are important in signalling pathways for many cellular functions. These include growth control, metabolism and translation of genes into proteins. Inhibition of any of these processes can result in tumour suppression. Atoms are represented as spheres and are colour-coded: carbon (light blue), hydrogen (white), nitrogen (dark blue), oxygen (red) and iron (green).
Size: 4680px × 3744px
Photo credit: © DR TIM EVANS/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: -, 1, 3-kinase, anti-cancer, artwork, background, biochemical, biochemistry, biologic, biological, biology, black, breast, buparlisib, cancer, cgi, chemical, chemistry, chemotherapy, clinical, cut, cut-, cut-outs, cutout, cutouts, development, digitally, digitally-generated, drug, experimental, generated, graphic, healthcare, illustration, image, inhibition, inhibitor, investigation, investigational, medical, medication, medicine, model, molecular, molecule, oncology, outs, pathway, pharmaceutical, pharmaceutics, pharmacological, pharmacology, phosphoinositide, pi3k, plain, research, signalling, space-fill, space-filled, spacefill, spacefilled, structure, targeted, test, testing, therapy, treatment, trial
